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RNA interferences targeting the Fanconi
anemia/BRCA pathway upstream genes reverse
cisplatin resistance in drug-resistant lung cancer cells
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Abstract
Background: Cisplatin is one of the most commonly used chemotherapy agent for lung cancer. The therapeutic
efficacy of cisplatin is limited by the development of resistance.
In this study, we test the effect of RNA interference (RNAi) targeting Fanconi anemia (FA)/BRCA pathway upstream
genes on the sensitivity of cisplatin-sensitive (A549 and SK-MES-1) and -resistant (A549/DDP) lung cancer cells to
cisplatin.
Result: Using small interfering RNA (siRNA), knockdown of FANCF, FANCL, or FANCD2 inhibited function of the FA/
BRCA pathway in A549, A549/DDP and SK-MES-1 cells, and potentiated sensitivity of the three cells to cisplatin. The
extent of proliferation inhibition induced by cisplatin after knockdown of FANCF and/or FANCL in A549/DDP cells
was significantly greater than in A549 and SK-MES-1 cells, suggesting that depletion of FANCF and/or FANCL can
reverse resistance of cisplatin-resistant lung cancer cells to cisplatin. Furthermore, knockdown of FANCL resulted in
higher cisplatin sensitivity and dramatically elevated apoptosis rates compared with knockdown of FANCF in A549/
DDP cells, indicating that FANCL play an important role in the repair of cisplatin-induced DNA damage.
Conclusion: Knockdown of FANCF, FANCL, or FANCD2 by RNAi could synergize the effect of cisplatin on
suppressing cell proliferation in cisplatin-resistant lung cancer cells through inhibition of FA/BRCA pathway.
Keywords: Chemoresistance, Cisplatin, Lung cancer, RNA interference, Fanconi anemia/BRCA pathway, Core
complex
Background
Cisplatin, a DNA cross-linking agent, is one of the most
commonly used drugs in the treatment of lung cancer,
including non-small cell lung cancer (NSCLC) and small
cell lung cancer (SCLC) [1, 2]. Although cisplatin-based
chemotherapy is used as the standard treatment for pa-
tients with advanced NSCLC and SCLC, patients re-
spond to the therapy had been more variable, and
essentially all patients relapse due to acquired drug re-
sistance [3, 4]. Thus, a great understanding of mecha-
nisms of cisplatin resistance are essential to provide a
strategy for sensitizing some drug-resistant tumor cells
and improve treatment of patients with lung cancer.
Cisplatin reacts with DNA to form intrastrand cross-
links, which constitutes about 85–90 % of all lesions,
and interstrand cross-links (ICLs) contributing about 1–
3 % to the total lesion burden [5–7]. It is ordinarily
thought that the intrastrand cross-links may be the
major type of DNA lesions responsible for the toxic ef-
fects of cisplatin. However, due to its severe suppressing
effect on replication and transcription and the compli-
cated character of its repair, the lower yield-forming
ICLs may greatly contribute to the toxicity of cisplatin
[6, 7]. There is accumulating evidence that cellular re-
sponse to cisplatin exposure include the activation of
multiple DNA repair pathway and enhancement of DNA
damage repair process [7, 8]. It has been reported that
cisplatin resistance can arise from changes that increase
a cell’s capacity to repair DNA damage [9, 10]. There-
fore, DNA damage repair is one of main cisplatin resist-
ant mechanisms. The DNA repair pathway that resolve
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DNA ICLs, such as homologous recombination (HR)
and translesion synthesis (TLS), are coordinated by a
DNA damage response pathway termed the Fanconi
anemia (FA)/BRCA pathway [11].
FA is a rare human genetic disease featured with se-
vere bone marrow failure, many congenital defects, and
an extremely high cancer incidence [12]. Cells from pa-
tients with FA display abnormally high sensitivity to
DNA ICL-inducing agents, such as cisplatin and mito-
mycin. Currently there are 16 verified FA genes that
make up the FA/BRCA pathway [13–17]. The FA pro-
teins encoded by these genes are thought to work co-
operatively in a common signaling pathway to repair
ICLs [8, 11]. Upon DNA damage or upon entry into the
S phase of the cell cycle, the core complex consists of
eight-protein (FANC-A, B, C, E, F, G, L, M) act as an E3
ubiquitin ligase to monoubiquitinate FANCD2 and its
paralog FANCI [18]. Monoubiquitinated FANCD2/I
complex is targeted to site of chromatin damage where
it recruits the downstream FA proteins (FANC-D1, N, J,
O, P) and additional DNA repair proteins such as
BRCA1. These downstream proteins participate in DNA
repair by HR or TLC [8, 11, 17–20]. Monoubiquitination
and nuclear foci formation of FANCD2 are central steps
in the activation of FA/BRCA pathway [8, 11]. Cells de-
fective in the upstream core complex are hypersensitive
to certain therapeutics, particularly ICL-inducing agents.
The extent of hypersensitivity depends on the specific
ICL-inducing agent used [21, 22] and the defective FA
protein [23].
It is realized that the integrity of the FA/BRCA path-
way is required for tumor resistance to cisplatin [8, 24].
Consequently, the FA gene knockdown by RNA interfer-
ence (RNAi) may sensitize tumor cells to cisplatin. Al-
though inhibition of FANCF is known to result in
FANCD2 ubiquitination inactivation and dysfunction of
the FA/BRCA pathway, which enhance the sensitivity of
cancer cells to DNA cross-linking agents, such as cis-
platin, mitomycin and melphalan in ovarian, breast can-
cer, and myelomas [25–27], little is known about which
gene depletion in the upstream core complex is of a
stronger sensitizing effect to cisplatin in drug-resistance
lung cancer cells. Therefore, we hypothesize that the
knockdown of the different genes in the upstream core
complex led to various degree sensitization to cisplatin
in lung cancer cells. In this study, we test the impact of
FANCF, FANCL and/or FANCD2 knockdown by small
interfering RNA (siRNA) on the FA/BRCA pathway
function and the sensitivity to cisplatin in human lung
cancer cells A549 (an adenocarcinoma cell line), A549/
DDP (a cisplatin-resistant A549 cell line), and SK-MES-1
(a squamous cancer cell line). Our data show that the
sensitization effect to cisplatin by depleting FANCF,
FANCL and FANCD2 in A549/DDP cells was significantly
greater than in A549 cells. The knockdown of FANCL dis-
play more significant sensitivity to cisplatin in A549/DDP
cells, as opposed to the depletion of FANCF, comparable
to that of the FANCD2, suggesting that the combination
of the gene therapy by depleting certain FA/BRCA path-
way upstream gene and cisplatin has synergistic anti-
tumor activity against cisplatin-resistant lung cancer cells.
Methods
Cell lines and culture conditions
Human lung caner cells A549 (an adenocarcinoma cell
line), A549/DDP (a cisplatin-resistant A549 cell line),
and SK-MES-1 (a squamous cancer cell line) were pur-
chased from the Shanghai Institute for Biological Science
(China). The cisplatin-resistant A549/DDP variant cell
line was established by continuous exposure to increas-
ing concentration of cisplatin for a 10 month period fol-
lowing the methodology reported previously [28]. The
characteristics of A549/DDP cells have been described
previously [29]. The cells were grown in RPMI-1640
complete medium supplemented with 10 % fetal calf
serum (Gibco) in a humidified atmosphere containing
5 % CO2 at 37 °C. A549/DDP cells medium additionally
contained 0.5 μg/ml cisplatin to maintain cells’ drug-
resistant phenotype. Cells in the logarithmic phase of
growth were used for all experiments. A549/DDP cells
were cultured in complete media without cisplatin for
5 days before performing experiments.
Small interfering RNA transfection
All siRNA used in this study were purchased from
Guangzhou Riboio Co., Ltd (China). The siRNA se-
quences used in this study are as follows: siRNAs
against FANCF were siRNA-1 5′-GGUCAACGUUUG
CACUAUG-3′, siRNA-2: 5′-GUACCUGGUCUUAGC
AUCU-3′ and siRNA-3: 5′-CUUCGUAGUGGUGCA
UUUA-3′; siRNAs against FANCL were siRNA-1 5′-
GACAAGAGCTGTATGCTCT-3′, siRNA-2: 5′-CTTG
CTGTGTGACTGTCAC-3′ and siRNA-3: 5′-CCAG
GAAGCAACCACTTTC-3′; siRNAs against FANCD2
were siRNA-1 5′-CCTCGTAGAAGCTTATCAA-3′,
siRNA-2 5′-GGTTGGCTTAATAAATTCA-3′ and siR
NA-3 5′-GCTCTTTCAACGTAAATTA-3′; and non-
targeting control siRNA, 5′-UAGCGACUAAACACAU
CAA-3′. The indicated siRNAs were synthesized by
Guangzhou Riboio Co., Ltd (China). Cell transfection
was performed using Lipofectamin 2000 according to
the manufacturer’s instructions. Cells were seeded in
free-antibiotics media at a concentration of 1 × 105/
well and cultured for 24 h before siRNA transfection.
Black control, non-targeting control, siRNA-1, siRNA-
2, and siRNA-3 groups were set up. Then cells were
mixed with 5 μ/ Lipofectamin TM 2000 and 5 μ/
siRNA, slightly waved and then incubated in 50 %
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CO2 at 37 °C for 6 h, after which the medium was
changed to complete medium and incubation was
continued for 48 h before harvesting cellular proteins.
Efficacy of siRNA transfection was evaluated by west-
ern blot and real-time quantitative RT–PCR. The tar-
get siRNA was chosen for further investigation as it
had the highest intereference efficiency.
All experiments in this study were performed in
triplicate.
Cell proliferation detection
The cell Counting-kit (CCK-8) assays were performed to
measure cell proliferation. A549 and A549/DDP cells
were seed at a density of 3 × 104 cells per well in 96-well
plates, and allowed to grow in the growth medium for
24 h. Cells were then treated with 20 μg/ml cisplatin
(He pharmaceutica Co., Ltd, China) with concentrations
ordinally diluted by 50 %. There was a negative control
with 0 μg/ml cisplatin. A blank group had no added
cells. The total medium volume of each well was 100 μl.
Two day after drugs addition, 10 μl of cell proliferation
reagent CCK-8 (DOJNDO, Japan) was added into media
in each well and the cell were incubated for 2 h at 37 °C.
The absorbance of each well was determined with a
spectrophotometer reading at a wavelength of 450 nm.
Absorbance is assumed to be directly proportional to
the number of viable cells. The IC50 was calculated as
the cisplatin concentration that kills 50 % of cells of un-
treated control.
Real-time quantitative-PCR analysis
Total RNA was extracted using a Trizol kit (Invitrogen,
CA, USA), and the concentration and purity of the re-
covered RNA were measured by UV-visible spectropho-
tometer (Bio-Tek). Then cDNA was synthesized from
total RNA using MML-RT reverse transcriptase in ac-
cordance with the manufacturr’s instructions.
The real-time quantitative (RTQ)-PCR of FANCF,
FANCL, and FANCD2 mRNA and β-actin as internal
control were carried out on an ABI 7500 Thermal Cycler
Real-time PCR system (Applied Biosystems, CA, USA),
using the SYBR-Green I chemistry. Amplification primers
of the three genes were synthesized by BioAsia Corpor-
ation (Shanghai, China) as follows: primer sequences for
FANCF were 5′-TGCTAACAGACTGGGGTCAAC-3′
and 5′-TACAGGTCTCCAGGGCAGTTA-3′, and for
FANCL, 5′-AAAGGCATTCTGGGATGTTTATG-3′ and




GGTGGACAGCGAGG-3′. The cycling conditions have
been described in detail in previous report [30]. Detection
of PCR products was accomplished by measuring the
emitting fluorescence (Rn) at the end of each reaction
step. Threshold cycle (Ct) corresponds with the cycle
number required to detect a fluorescence signal above the
baseline. Relative quantification was calculated with the Ct
(2—△△Ct) method [31].
Western blot assay
Western blot analyses were performed to detect FANCD2
monoubiquitination and FANCF, FAMCL, FANCD2,
cleaved-caspase-3, caspase-9, and poly ADP-ribose poly-
merase (PARP) proteins. Total cell extracts were obtained
by direct lysis of cells in lysis buffer (50 mM Tris HCl,
150 mM NaCl, 10 mM β-glycerophosphate, 1 % NP-40,
1 μg/ml aprotinine, 1 μg/ml leupeptine, 1 μg/ml pepsta-
tine, 0.5 mg/ml pefabloc, and 1 mM Na3VO4) boiled for
5 min, and subjected to polyacrylamide SDS gel electro-
phoresis (Sigma Co., USA). After electrophoresis, proteins
were transfer to Immobilonp-FL transfer membranes
(Sigma Co., USA). The membranes were then blocked
with 5 % nonfat dried milk in PBS-T overnight at 4 °C and
then incubated at room temperature for 1 h or over-
night at 4°Cin appropriate primary antibody diluted in
PBS-T. After three times 5 min washes in PBS-T,
membranes were then incubated for 1 h at room
temperature in appropriate secondary antibody at a
dilution of 1:2000 in PBS-T + 0.5 % milk. Finally, blots
were washed five times for 5 min in PBS-T, and films
were developed by using the ECL Western Blot Ana-
lysis System (Beijing Sage Creation Technology Co.,
Ltd, China). Immunoblots were probed with the fol-
lowing primary antibodies: FANCF, FANCL, FANCD2
(Santa Cruz and Rockland, USA), and cleaved-
caspase-3, caspase-9, and PARP (Cell Signaling Tech-
nology, USA).
Immunofluorescence analysis
Immunofluorescence techniques were used to analyze
FANCD2 nuclear foci formation. Cells were seed on
glass coverslips and incubated overnight before or after
treatment with different concentration of cisplatin for
24 h. Cells were then rinsed with PBS three times and
fixed with 4 % paraformaldehyde in PBS for 15 min at
4 °C. The fixed cells were permeabilized with 0.3 %
Triton-x-100 (Sigma, USA) in PBS for 20 min on ice.
After blocking in 30 % BAS for 1 h at room temperature,
anti-FANCD2 antibodies (Santa Cruz, USA) were added
at dilution of 1:200. After overnight incubation at 4 °C,
cells were washed three times with PBS and then incu-
bated with fluorescent secondary antibodies (Sigma,
USA) for 1 h at 37 °C. Then cells were rinsed with PBS
three times. Glass coverslips were mounted in Vecta-
shied containing DAPI. Images were captured with a
Nikon fluorescence microscope and analyzed using
Adobe Photoshop software (Axanoae, USA).
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Flow cytometry analysis of apoptosis
The percentage of apoptosis cells induced following cis-
platin treatment was determined by flow cytometry with
Annexin V-FITC/PI staining. Exponential growing cells
were seeded in drug-free media at a concentration of
1 × 105 cells/well overnight before experiment and then
treated with different concentration of cisplatin for 48 h.
After treatment, the cells were harvested, washed twice
with PBS and resuspended in the provided binding buf-
fer and subsequently staining with Annexin V-FITC (5-
μg/ml) and incubated for 15 min in the dark at room
temperature. Afterwards, the cells were analyzed by flow
cytometry (BD Co., USA).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 ver-
sion. All values were expressed as means ± standard
error of the mean (SEM). Comparisons between two
groups were conducted by unpaired t test. Group differ-
ences resulting in P < 0.05 were considered to be statisti-
cally significant.
Results
Cisplatin resistant A549/DDP cells have enhanced
function of FA/BRCA pathway
Using CCK-8 assay, we compared cisplatin sensitivity in
the drug-sensitive and drug-resistant lung cancer cells.
As expected, A549/DDP cells had increased prolifera-
tion rates compared with their drug-sensitive parental
A549 cells 24 and 48 h after cisplatin treatment in a
concentration-dependent manner (Fig. 1a). The full
integrity of the FA/BRCA pathway is needed for tumor
cell resistance to ICL-inducing agents and activation
extent of FA/BRCA pathway depend on the level of
FANCD2 monoubiquitination [11]. To determine whether
the activation degree of the FA/BRCA pathway is associ-
ated with cisplatin resistance in A549/DDP cells, we tested
FANCD2 monoubiquitination after treatment with various
concentration of cisplatin in the two cells. The results
showed that the levels of FANCD2 monoubiquitina-
tion induced by cisplatin in A549/DDP cells, as indi-
cated by the ratio of FANCD2-L (monoubiquitinated
form of FANCD2) to FANCD2-S (unubiquitinated form
of FANCD2), were much higher than those in A549 cells
(Fig. 1b-d). Immunofluorescent techniques were used to
analyze FANCD2 nuclear foci formation, a hallmark of
Fanconi anemia pathway activation. Cisplatin-induced
FANCD2 foci formation, as measured by percentage of
cells with greater than five foci, was found to be signifi-
cantly increased in A549/DDP cells than in A549 cells
(Fig. 2). These results indicate that A549/DDP cells have
more marked activation of FA/BRCA pathway and stron-
ger capability of DNA damage repair as compared with
A549 cells, and also imply that the FA upstream protein
participate in cisplatin resistance and upregulatory func-
tion of the FA/BRCA pathway may contribute to en-
hanced ICL repair capacity in A549/DDP cells.
Efficiency of FANCF, FANCL and FANCD2 gene
knockdown by siRNA
In order to assess the role of FANCF, FANCL, and
FANCD2 in the sensitivity of lung cancer cells to cis-
platin, we designed three different siRNA sequences
(siRNA-1, siRNA-2, siRNA-3) for each gene to knock-
down the three genes respectively in A549 cells. The ex-
pression levels of both protein and mRNA of them were
Fig. 1 The proliferation rates and FANCD2 monoubiquitination in A549 and A549/DDP cells treated with DDP. a The proliferation rates in A549/DDP
cells 24 and 48 h after cisplatin treatment were significantly higher than those in A549 cells. b FANCD2 monubiquitination in A549 cells induced by
cisplatin with different concentrations. c FANCD2 monubiquitination in A549/DDP cells induced by cisplatin with different concentrations. d The levels
of FANCD2 monoubiquitination in A549/DDP cells were markedly higher than those in A549 cells after cisplatin treatment
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determined after the trasfection of different siRNAs
for 48 h. As shown in Fig. 3a, b, the FANCF-siRNA-3
and FANCL-siRNA-3 significantly down-regurated both
mRNA and protein expression levels of FANCF and
FANCL, compared with FANCF-siRNA-1 or -siRNA-2
and FANCL-siRNA-1 or -siRNA-2. Therefore, FANCF-
siRNA-3 and FANCL-siRNA-3 were selected for followed
investigation. Meantime, western blot and QRT-PCR ana-
lysis showed that the interference efficiency of FANCD2-
siRNA-2 was the highest among three siRNAs against
FANCD2 (Fig. 3c), thus FANCD2-siRNA-2 was chosen as
the target siRNA for further experiments. In addition,
there was no significant difference in expression levels of
the three genes between the black control group and non-
targeting control group.
Knockdown of FANCF, FANCL, or FANCD2 enhance
sensitivity of A549 and SK-MES-1 cells to cisplatin
Using RNAi approach, we knocked down the expression
of FANCF, FANCL, and FANCD2 in A549 cells. As
shown in Fig. 4a, depletion of FANCF or FANCL indi-
vidually sensitized A549 cells to cisplatin. Although cells
depleted of FANCL appear to be more sensitive to cis-
platin than cells depleted of FANCF, difference in the
IC50 between the two cells did not reach statistical sig-
nificance (Table 1). Moreover, individual depletion of
FANCF or FANCL from these cells and the double de-
pletion of both FANCF and FANCL resulted in compar-
able hypersensitivity to cisplatin (Fig. 4a and Table 1).
These data indicate that FANCF and FANCL function in
a common pathway, or at least a partially overlopping
pathway in the repair of DNA ICLs. The notion was
demonstrated by the results of Western blot analysis,
which shown that the level of FANCD2 monoubiquitina-
tion induced by cisplatin was dramatically and similarly
reduced in A549 cells individually depleted of FANCF
and FANCL (Fig. 4b, c). Furthermore, the double deple-
tion of FANCF and FANCL did not further reduce
FANCD2 monoubiquitination (Fig. 4b, c).
Meanwhile, we assessed the impact of FANCD2 sta-
tus on the ability of DNA ICLs repair and the cell
proliferation after treatment with cisplatin. As seen in
Fig. 4d, A549 cells lacking FANCD2 were remarkably
sensitive to the antiproliferative effects of this ICLs
Fig. 2 Immunofluorescence and quantification of cells exhibiting 5 or more FANCD2 foci in lung cancer cells. Cisplatin-induced FANCD2 foci
formation in A549 (a) and A549/DDP cells (b) were inhibited markedly by knockdown of FANCF, FANCL, and FANCD2. c The graph below show
quantified data of FANCD2 foci in the two cells. cisplatin-induced FANCD2 foci expressions were stronger in A549/DDP than in A549 cells
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agent. Co-depletion of FANCD2 and FANCF, or and
FANCL did not cause more profound sensitization to
cisplatin (Fig. 4d, Table 1). Given that these gene
knockdowns were highly effective, the results confirm
that FANCF and FANCL are epistatic of FANCD2
and are involved in the same pathway to confer toler-
ance of cisplatin-induced DNA damage. Consistently,
co-depletion of both FANCD2 and FANCF, or FANCL
produced no additional decrease of FANCD2 monou-
biquitination levels upon DNA damage induced by
cisplatin, when compared with depletion of FANCD2
alone (Fig. 4e, f ). Additionally, cisplatin-induced FANCD2
foci formation was inhibited by depleting FANCF, FANCL,
or FANCD2 in similar degree (Fig. 2a, c), which were
identical with results of FANCD2 monoubiquitination
analyses.
SK-MES-1 cell is a lung squamous cancer cell which
display slight resistance to cisplatin (IC = 9.92 ± 0.35,
Table 1) compared with A549 cell (IC = 4.97, Table 1).
We examined the change of sensitivity in SK-MES-1
cells by knocking down FANCF, FANCL, and FANCD2
using siRNA transfection, and observed FANCD2 mono-
ubiquitination levels. The results showed that individual
and double knockdown of FANCF, or FANCL, or
FANCD2 markedly enhanced the sensitivity of SK-MES-
1 cells to cisplatin, and reduced the levels of FANCD2
monoubiquitination (Fig. 5a-f ), which are in line with
the findings in A549 cells.
Knockdown of FANCL results in higher cisplatin sensitivity
compared with knockdown of FANCF in A549/DDP cells
The above-mentioned experimental results have shown
that FA/BRCA pathway involved the sensitivity to cis-
platin in drug-resistant A549/DDP cells. We next ex-
plored relative roles of FANCF and FANCL in the
sensitivity to cisplatin by depleting FANCF only, FANCL
only, or both the two core complex components, and
testing cisplatin-induced cell proliferation in A549/DDP
cells. As shown in Fig. 6a, siRNA mediated depletion of
FANCF or FANCL significantly sensitized A549/DDP
cells to cisplatin. It is worth noting that cells depleted of
FANCL were more sensitive to cisplatin than those de-
pleted of FANCF. As seen in Table 1, the IC50 value in
FANCF depleted cells was significantly higher than that
in FANCL depleted cells (P < 0.001). But co-depletion of
FANCF and FANCL did not produce any additional sen-
sitivity over that of FANCL. The differential sensitization
suggests that FANCL has an epistatic yet more import-
ant role than FANCF in cellular resistance to cisplatin.
Moreover, western blot and immunofluorescence assay
Fig. 3 Expression of FANCF, FANCL and FANCD2 in A549 cells after siRNA transfection. The protein and mRNA relative expression levels of FANCF
(a) and FANCL (b) were the lowest by using siRNA-3 transfection among three-different siRNA transfections. c The protein and mRNA expression
inhibitions of FANCD2 were the strongest by using siRNA-2 transfection among three-different siRNA transfections. BC: black control; NC:
non-target control
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revealed that individual or double depletion of
FANCF and FANCL resulted in significant decrease of
FANCD2 monoubiquitination levels (Fig. 6b, c) and in-
hibition of FANCD2 foci formation (Fig. 2b, c).
Additionally, we found that reduced extent of prolifer-
ation rate induced by cisplatin treatment in A549/DDP
cells was significantly greater than in A549 cells after
knockdown of FANCF or FANCL (Fig. 4a and 6a,
Table 1), suggesting that knockdown of FANCF or
FANCL can reverse resistance of cisplatin-resistant lung
cancer cells to cisplatin, whereas the knockdown of the
two genes in cisplatin-sensitive lung cancer cells only
moderately increase sensitivity to cisplatin.
Knockdown of FANCD2 lead to a similar cell sensitivity to
that of FANCL in A549/DDP cells
We also evaluated the sensitizing effect of FACD2
knockdown on cisplatin in A549/DDP cells. As shown in
Fig. 6d, depletion of FANCD2 remarkably reduced cell
proliferation rate after cisplatin treatment. Nevertheless,
depletion of FANCD2 alone, or co-depletion of FANCD2
and FANCF, or and FANCL exhibited a similar reduc-
tion in cell proliferation following cisplatin treatment.
Consistent with the sensitization effects of these gene
knockdowns on cisplatin, cells depleted of FANCD2
alone, and cells co-depleted of both FANCD2 and
FANCF, or FANCL, had nearly identical decrease of
Fig. 4 The effect of FA upstream gene knockdowns on proliferation and FANCD2 monoubiquitination in A549 cells. a Knockdowns of FANCF,
FANCL, or both them inhibited the proliferation rates, and (b, c) reduced FANCD2 monoubiquitination levels after cisplatin treatment. d
Knockdown of FANCD2, or double knockdown of FANCD2 and FANCF, or and FANCL suppressed the proliferation rate, and (e, f) dropped
FANCD2 monoubiquitination levels after cisplatin treatment
Table 1 The 50 % inhibitory concentration (IC50) of cisplatin in A549 and A549/DDP cells 48 h after drug treatment
Cell Control siFANCF siFANCL siFANCF+ siFANCD2 siFANCD2+ siFANCD2+
siFANCL siFANCF siFANCL
A549 4.97 ± 0.32 3.05 ± 0.24a 2.46 ± 0.21b 2.44 ± 0.27 b 2.48 ± 0.31 b 2.45 ± 0.18 b 2.40 ± 0.23 b
A549/DDP 34.15 ± 0.42 4.43 ± 0.28c 2.51 ± 0.33c, d 2.48 ± 0.25 c, d 2.54 ± 0.17 c, d 2.52 ± 0.22 c, d 2.47 ± 0.19 c, d
SK-MES-1 9.92 ± 0.35 3.47 ± 0.25c 2.68 ± 0.29c 2.45 ± 0.32c 2.58 ± 0.23c 2.50 ± 0.33c 2.46 ± 0.35c
acompared with control, p = 0.009; bcompared with control, p = 0.001; ccompared with control, p < 0.001; dcompared with siFANCF, p < 0.001
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FANCD2 monoubiquitination (Fig. 6e, f ). Moreover, the
IC50 value of FANCD2 knockdown cells was similar to
that of FANCL depleted cells, but significantly lower
than that of FANCF depleted cells (P < 0.001) (Table 1).
Taken together, these results further support the idea
that FANCF and FANCL are epistatic to FANCD2, and
FANCF and FANCL function in a common pathway, but
FANCL may play a more important role in facilitating
FANCD2 monoubiquitination.
Knockdown of FA upstream proteins promotes apoptosis
of A549/DDP cells
To explore whether effect of proliferative inhibition in
cisplatin-resistant lung cancer cells by depleting FANCF
or FANCL was associated with apoptosis, we detected
the apoptosis rate of the A549/DDP cells induced by cis-
platin following depletion of the two genes. As shown in
Fig. 7, compared with the control, depletion of FANCF
or FANCL in A549/DDP cells significantly increased the
percentage of both early and late apoptosis cells after
cisplatin treatment in a concentration-dependent man-
ner (Fig. 7a-d, P = 0.001 and P < 0.001). Furthermore, the
percentages of apoptosis cells in FANCL depleted cells
were markedly higher than those in FANCF depleted
cells, when treatment with 10 μg/ml and 20 μg/ml cis-
platin (Fig. 7d, P = 0.001 and P < 0.001), indicating that
knockdown of FANCF or FANCL by siRNA could syner-
gize the effect of cisplatin on inducing apoptosis of
cisplatin-resistant lung cancer cells through suppressing
FA/BRCA pathway. To investigate if the apoptosis
caused by depleting FANCF or FANCL is caspase-
dependent, we analyzed caspase-dependent apoptpsis-
associated proteins by western blot. The results showed
that depletion of FANCF and FANCL clearly increased
the levels of cleaved caspase-3, caspase-9, and PARP
proteins in A549/DDP cells (Fig. 8a, b), indicating that
Fig. 5 The effect of FA upstream gene knockdowns on proliferation and FANCD2 monoubiquitination in SK-MES-1 cells. a Knockdowns of FANCF,
FANCL, or both them inhibited the proliferation rates, and (b, c) reduced FANCD2 monoubiquitination levels after cisplatin treatment. (d) Knockdown
of FANCD2, or double knockdown of FANCD2 and FANCF, or and FANCL suppressed the proliferation rate, and (e, f) dropped FANCD2
monoubiquitination levels after cisplatin treatment
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knockdown of FANCF and FANCL activate caspase-
dependent apoptosis.
Discussion
Increasing evidences indicate that cancer cell resistance
to cross-links agents, such as cisplatin, is linked to the
functional status of the FA/BRCA pathway [8, 11, 25–
27], albeit the exact mechanism of this resistance to the
chemical crosslinker remains to be fully elucidated. In
this study, we confirm that upregulation of FANCD2
monoubiquitination and activation of FA/BACA path-
way contributes to acquired resistance to cisplatin for
lung cancer A549/DDP cells. Moreover, we show that
knockdown of FANCF and/or FANCL by siRNA potenti-
ates sensitivity to cisplatin in cisplatin-sensitive and -re-
sistant lung cancer cells.
Within the FA/BRCA pathway, eight upstream FA
protein and some FA-associated proteins form a
ligase core complex that monoubiquitinates both com-
ponents of the ID complex, FANCD2 and FANCI, in
response to DNA damage and replication stress during
S phase. The FA core complex mainly comprises three
subunits, including FANCB-FANCL-FAAP100 (B-L-100),
FANCC-FANCE-FANCF (C-E-F) and FANCA-FANCG-
FAAP20 (A-G-20) [32–37]. It is generally thought that a
single mutation in any of the FA upstream genes that
make up the core complex prevents the FANCD2 monou-
biquitination event from occurring. FANCF had been im-
plicated in the physical stability of the majority of other
core complex proteins, FANCC, FANCE, FANCG and
FANCA by several groups and functions as a adaptor that
is essential for the integrity of the core complex and the
monoubiquitination of FANCD2 [34, 38]. FANCL is con-
sidered a key component of the FA core complex and rep-
resent the E3 ligase necessary for ubiquitin conjugation to
lysine 561 of FANCD2 and lysine 523 of FANCI [39, 40].
The depletion of FANCF gene results in the inhibition of
FANCD2 monoubiquitination and the enhancement of
sensitivity to DNA cross-linking agents (melphalan, cis-
platin and mitomycin) in myeloma, ovarian and breast
cancer cells [25–27]. In line with these reports, we results
show that knockdown of FANCF sensitized drug-sensitive
and -resistant lung cancer cells to cisplatin and diminished
the levels of FANCD2 monoubiquitination. Similarly,
Fig. 6 The effect of FA upstream gene knockdowns on proliferation and FANCD2 monoubiquitination in A549/DDP cells. a Knockdown of
FANCF, FANCL, or both them markedly inhibited the proliferation rates, and (b, c) reduced FANCD2 monoubiquitination levels after treatment
with cisplatin. (d) Knockdown of FANCD2, or double knockdown of FANCD2 and FANCF, or and FANCL significantly suppressed the proliferation
rates, and (e, f) reduced FANCD2 monoubiquitination levels after treatment with cisplatin
Dai et al. Journal of Biomedical Science  (2015) 22:77 Page 9 of 13
Fig. 7 (See legend on next page.)
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knockdown of FANCL increase sensitivity to cisplatin in
the lung cancer cells. However, the sensitization effect to
cisplatin by depleting FANCF or FANCL in A549/DDP
cells was more significant as compared with A549 and
SK-MES-1 cells. For instance, the IC50 values of A549/
DDP cells transfected with FANCL-siRNA were reduced
from 34.15 μg/ml pre-transfection to 2.51 μg/ml post-
transfection, whereas the IC50 values of A549 cells pre-
and post-transfection were 4.97 μg/ml and 2.46 μg/ml, re-
spectively (Table 1). Also, the dropped extent of FANCD2
monoubiquitination levels in A549/DDP cells was greater
than in A549 cells following depletion of FANCF and/or
FANCL. The results suggest that enhanced E3 ligase activ-
ity of the core complex in A549/DDP cells might be re-
sponsible for cisplatin resistance, and the suppression of
the core complex ligase activity and downregulation of
FANCD2 monoubiquitnation by siRNA targeting FANCF
or FANCL can reverse resistance of cisplatin-resistant
lung cancer cells to cisplatin.
In this study, another interesting finding is that knock-
down of FANCL led to more dramatic sensitization
effect on cisplatin compared with knockdown of FANCF
in A549/DDP cells. The IC50 value of depleted FANCF
A549/DDP cells was markedly higher than that of
depleted-FANCL cells 48 h after cisplatin treatment.
Moreover, apoptosis rates of A549/DDP cells depleted of
FANCL were significantly elevated following cisplatin
treatment, not only compared with those of control, but
also compared with those depleted of FANCF. But co-
depletion of FANCF and FANCL did not have a signifi-
cantly additive impact on sensitivity to cisplatin. This
phenomenon was different from A549 cells, in which in-
dividual knockdown of FANCF and FANCL, or in com-
bination, resulted in comparable cisplatin sensitivity and
levels of FANCD2 monoubiquitination. These finding
suggest that FANCL may play a notably important role
for acquired resistance to cisplatin in A549/DDP cells,
although FANCF and FANCL were epistatic and act in
the common FA/BRCA pathway.
A recent study shown that not all the components of
the core complex contribute equally to cellular resist-
ance against DNA damage [23], even though the study
(See figure on previous page.)
Fig. 7 Knockdown of FANCF and FANCL promote the apoptosis induced by cisplatin in A549/DDP cells. a The apoptosis rates of control cells, and (b)
cells transfected with FANCF-siRNA, and (c) cells transfected with FANCL-siRNA after cisplatin treatment. Early apoptotic cells are in the lower right
quadrant; late apoptotic cells are in the upper right quadrant. d The apoptosis rates in cells transfected with FANCF-siRNA or FANCL-siRNA were
significantly higher than in control cells in a concentration-dependent manner. In addition, the apoptosis rates of cells transfected with FANCL-siRNA
have dramatic increase as compared with cells transfected with FANCF-siRNA following treatment of 10 μg/ml and 20 μg/ml cisplatin
Fig. 8 Caspase-3, caspase-9, and PARP expressions were detected by Western blot in A549/DDP cells. a The expressions of cleaved caspase-3,
caspase-9, and PARP induced by cisplatin were elevated after siFANCF transfection. b The expressions of cleaved caspase-3, caspase-9, and PARP
induced by cisplatin were increased after siFANCL transfection
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results deviates from a general idea that losing any one
of the core comlex components results in complete
elimination of FANCD2 activation and disintegration of
the core complex. The study reported that the subunits
in core complex are of different function and the overall
integrity of the core complex is sustained when certain
FA proteins are removed. Among these subunits, FANCB,
L and FAAP100 constitute a catalytic subunit that is abso-
lutely required for the E3 ligase activity of the core com-
plex, whereas the A-G-20 and C-E-F subunits provide
non-redundant and ancillary functions that help the cata-
lytic subunit bind chromatin or site of DNA damage [23].
Also, other recent studies suggest a key role of FANCL as
the E3 ligase in the monoubiquitination of FANCD2 and
activation of FA/BRCA pathway. For instance, DT40 cells
(a chicken somatic cell) lacking FANCL, B, or FAAP100
completely lost the ability to monoubiquitinate FANCD2,
implying that subunit is indispensable for FANCD2 mon-
ubiquitination. However, FANCD2 monoubiquitination
activity in cells depleted of FANCC and FANCF was com-
parable to the wild–type cells [37]. Furthermore, the study
found that in comparison to wild-type cells, residual
chromatin-associated FANCD2 monoubiquitination was
still present in the cells lacking FANCA, FANCG, FANCF,
or FANCC [37]. Therefore, loss of different FA core com-
ponents produces variable impact on the activation of the
FA/BRCA pathway and correspondingly variable cellular
sensitivity to cross-linking agents. Perhaps these findings
may explain our results that depletion of FANCL had a
more potent sensitization on A549/DDP cells than knock-
down of FANCF. However, it is unclear why there was no
significant difference for the sensitivity of A549 cells to
cisplatin between knockdown of FANCF and FANCL. But
it is known that cisplatin-induced DNA cross-links might
be repaired by FANCF and FANCL which are components
of FA core complex. FANCF might play a minor role in
the repair pathway for cisplatin-induced damage, whereas
FANCL play a crucial role as mentioned above. The differ-
ence for repair capacity of DNA damage between FANCF
and FANCL might be more significant in cisplatin-
resistant lung cancer cells. Further study is required to as-
certain the precise mechanism that DNA repair activities
of FA/BRCA pathway in cisplatin-resistant cells differ
from cisplatin-sensitive cells.
It is known that monoubiquitinated FANCD2-I (ID)
complex is at the heart of the FA/BRCA pathway. The
monoubiquitination of FANCD2 at lysine 561 is essential
for the downstream function of the pathway in DNA
damage repair [41]. Cells expressing k561R FANCD2,
which is a mutant form of FANCD2 and cannot be
monoubiquitinated, have increased sensitivity to cross-
linking agent compared with wild-type FANCD2 [41].
Consistent with previous reports using other cells [42,
43], siRNA-mediated depletion of FANCD2 potently
sensitized A549, A549/DDP and SK-MES-1 cells to cis-
platin, which is similar to the sensitization of the three
cells to cisplatin by depleting FANCL. As expected, we
did not observe further sensitization of the three cells
to cisplatin upon treatment with double depletion of
FANCD2 and FANCF, or FANCL, further supporting
the notion that FANCD2, FANCF and FANCL act in
a common DNA repair pathway.
Cisplatin-based combination chemotherapy is the first-
line therapy for SCLC and advanced NSCLC. Despite
considerable success in treatment of lung cancer, the ef-
fectiveness of cisplatin in clinics has been limited by the
resistance that cancer cells developed during the course
of chemotherapy. Thus, overcoming tumor cells resist-
ance to cisplatin using RNAi targeting the FA upstream
genes in combination with cisplatin is a promising strat-
egy for treating lung cancer. With recent advance in
gene therapy techniques, improvements of in vivo RNAi
delivery methodologies indicate that adjuvant siRNA
therapy may be achievable in accessible tumor sites [44].
Further investigations are warranted to determine whether
the gene therapy by targeting the FA/BRCA pathway com-
bined with chemotherapy can used as an effective novel
therapeutic regimen for patients with lung cancer,
particular those with tumor relapse or progression
after chemotherapy.
Conclusion
In summary, we herein report that depletion of FANCF,
FANCL, or FANCD2 by using RNAi could reverse cis-
platin resistance in cisplatin-resistant lung cancer cells
through inhibition of FA/BRCA pathway. Moreovre,
knockdown of FANCL resulted in higher cisplatin sensi-
tivity and dramatically elevated apoptosis rates compared
with knockdown of FANCF, indicating that FANCL play
an important role in the repair of cisplatin-induced DNA
damage. Targeting of the FA/BRCA pathway may consti-
tute a potential treatment modality for lung cancer.
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